Author Archives: Warren Woessner

Ex parte Ren-Hie Xu – Are Cultured Mammalian Cells Natural Products?

Posted on March 27, 2019 by Warren Woessner

The Examiner in Appeal no. 2017-003416 (Mar. 1, 2019) had rejected this claim as directed to a natural product: “18. An in vitro culture comprising a substantially pure, replenishable population of synchronous primate trophoblast cells, wherein the synchronous primate trophoblast … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment

Ex parte Hazokaki – Big Data Correlations in Abstract Idea “Clothing”

Posted on March 25, 2019 by Warren Woessner

In earlier posts, I discussed at least one group of claims directed to the difficulties in claiming manipulations of “big data.” In ex parte Hazokaki, Appeal 2018-003293 (PTAB, Feb. 5, 2019), the Examiner and the Board were confronted with claims … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Split Federal Circuit Panel Holds That Method of Medical Treatment Claims are Patent Eligible

Posted on March 18, 2019 by Warren Woessner

In Natural Alternatives Int’l., Inc. v. Creative Compounds, LLC, Appeal No. 2018-1295 (Fed. Cir., March 15, 2019) a divided panel of the Fed. Cir. held that claims to methods of increasing the anaerobic working capacity in a human subject by … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

Hikma and West-Ward v. Vanda – Are Methods of Medical Treatment Patent-Eligible?

Posted on March 5, 2019 by Warren Woessner

Hikma Pharms. and West-Ward Pharms petition for cert. to reverse the Fed. Cir.’s decision in Vanda v. West-Ward that methods of medical treatment are patentable. The Supreme Court’s now-infamous Mayo decision, invalidated claims to a method for determining the optimal … Continue reading →

Posted in 2017 Patent Review | Tagged , , , , , | Leave a comment